Skip to content


Sarclisa (isatuximab) is an antibody pharmaceutical. Isatuximab was first approved as Sarclisa on 2020-03-02. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. The pharmaceutical is active against ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.
Trade Name Sarclisa
Common Name Isatuximab
Indication multiple myeloma
Drug Class Monoclonal antibodies: chimeric, tumors as target
Get full access now